MOUNTAIN VIEW, Calif., Dec. 14 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a privately-held, product based biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases, today announced that it will take part in a group panel discussion at the 2006 RBC Capital Markets Healthcare Conference which is being held December 13-14 at the Westin New York at Times Square Hotel in New York City. Timothy S. Nelson, MAP Pharmaceuticals' President and CEO, will participate in the panel discussion entitled "Breathing Easier: Innovative Approaches to Asthma" on Thursday, December 14, 2006, at 1:00 pm (ET).
About MAP Pharmaceuticals, Inc.
Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held, product based biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases. The Company has two Phase 2 clinical development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of an inhaled ergot alkaloid for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com .
MAP Pharmaceuticals, Inc.CONTACT: media, Lisa Johnson of MAP Pharmaceuticals, Inc.,+1-650-386-3122, or ljohnson@mappharma.com
Web site: http://www.mappharma.com/
